Skip to main content
. 2021 Aug 25;54:101329. doi: 10.1016/j.molmet.2021.101329

Figure 1.

Figure 1

Cellular model for FoxO-mediated beta-cell dedifferentiation. A. Schematic overview of our cellular model for FoxO-mediated beta-cell dedifferentiation, with potential to screen for inhibitors. B. Transcription of Ins2, Gcg, and Ngn3 in Min6 cells after two-day FoxO inhibitor (FoxOi, 1 μM unless otherwise stated) treatment, as measured by qPCR. C. Western blot of glucagon and insulin protein expression in Min6 cells following two-day FoxO inhibitor treatment. D. Measurement of insulin and glucagon intensity in Min6 cells treated with FoxO inhibitor at the single cell level, as quantified by immunofluorescence. E. Representative images of Min6 cells stained for insulin and glucagon after two-day treatment. Scale bars = 10 μm. F. RNAseq transcriptional expression changes in pancreatic endocrine factors after two-day FoxOi treatment versus control DMSO treatment in Min6 cells. All RNAseq results are representative of three biological replicates (n = 3). G. Gene set enrichment analysis (GSEA) showing downregulation of mouse (left) [58,59] and human (right) [61] beta-cell-specific genes with FoxO inhibitor treatment.